These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24393552)

  • 21. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular design for enhancement of ocular penetration.
    Shirasaki Y
    J Pharm Sci; 2008 Jul; 97(7):2462-96. PubMed ID: 17918725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
    Babizhayev MA; Kasus-Jacobi A
    Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biological availability of ophthalmic drugs. 1. Increasing drug permeability in the cornea].
    Masteiková R; Chalupová Z; Savickiene N
    Ceska Slov Farm; 2004 Mar; 53(2):73-9. PubMed ID: 15095575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Modeling of Ocular Pharmacokinetics and Adverse Effects.
    Ghemtio L; Xhaard H; Urtti A; Kidron H
    Curr Pharm Des; 2016; 22(46):6928-6934. PubMed ID: 27669964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimizing systemic absorption of topically administered ophthalmic drugs.
    Urtti A; Salminen L
    Surv Ophthalmol; 1993; 37(6):435-56. PubMed ID: 8100087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Transcorneal drug delivery: prospects for the use of liposomes].
    Aliautdin RN; Iezhitsa IN; Agarval R
    Vestn Oftalmol; 2014; 130(4):117-22. PubMed ID: 25306734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent patents and advances in ophthalmic drug delivery.
    Janoria KG; Hariharan S; Dasari CR; Mitra AK
    Recent Pat Drug Deliv Formul; 2007; 1(2):161-70. PubMed ID: 19075883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition.
    Sugiura T; Kato Y; Tsuji A
    J Control Release; 2006 Nov; 116(2):238-46. PubMed ID: 16876283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of blood-ocular barrier transporters in retinal drug disposition: an overview.
    Tomi M; Hosoya K
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1111-24. PubMed ID: 20438316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic ocular pharmacotherapy.
    O'Brien TP; Reynolds LA
    J Ophthalmic Nurs Technol; 1995; 14(4):160-4. PubMed ID: 7650747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.
    Nakano M; Lockhart CM; Kelly EJ; Rettie AE
    Drug Metab Rev; 2014 Aug; 46(3):247-60. PubMed ID: 24856391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits.
    Tajika T; Isowaki A; Sakaki H
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):43-9. PubMed ID: 21118027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of dorzolamide hydrochloride on ocular tissues.
    Inoue J; Oka M; Aoyama Y; Kobayashi S; Ueno S; Hada N; Takeda T; Takehana M
    J Ocul Pharmacol Ther; 2004 Feb; 20(1):1-13. PubMed ID: 15006154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ophthalmic drug delivery systems--recent advances.
    Bourlais CL; Acar L; Zia H; Sado PA; Needham T; Leverge R
    Prog Retin Eye Res; 1998 Jan; 17(1):33-58. PubMed ID: 9537794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent developments in ocular drug delivery.
    Chen H
    J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transient analysis of ocular drug delivery: zero-volume effect.
    Keister JC; Heidmann PS; Missel PJ
    J Pharm Sci; 1997 Sep; 86(9):1040-5. PubMed ID: 9294819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based ocular pharmacokinetic modeling using computational methods.
    Missel PJ; Sarangapani R
    Drug Discov Today; 2019 Aug; 24(8):1551-1563. PubMed ID: 31319151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ocular pharmacokinetics: Topical, intravitreal, and systemic drug application].
    Meyer CH; Krohne TU
    Ophthalmologe; 2014 Feb; 111(2):104-6. PubMed ID: 24510172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.